Three FDA metabolic approvals
Three FDA moves landed: clearance for a 1‑year implantable CGM (Eversense 365), clearance of a smaller smartphone‑controlled MiniMed Flex pump, and approval of oral semaglutide for weight loss—each expands the toolset for diabetes and metabolic care. Those approvals signal faster patient adoption and more longitudinal data sources relevant to health analytics integration. (pharmacytimes.com) (hcplive.com) (ajmc.com)
Senseonics’ Eversense 365 was cleared by the FDA on September 17, 2024 as the first continuous glucose monitor with a single sensor designed to last 365 days. (senseonics.com) Senseonics transitioned global commercialization of Eversense back in‑house effective January 1, 2026 and entered that move after a $78 million financing and an expanded $100 million debt facility, a shift BTIG said should enable higher revenue recognition and gross‑margin leverage. (mddionline.com) Real‑world data presented for the Eversense 365 at recent clinical meetings show sustained year‑long sensor performance and the system is FDA‑cleared as an iCGM with AID/pump compatibility (including announced integration with Sequel’s twiist), while Senseonics lists a patient discount program of $199/year and an unsubsidized transmitter price near $1,000. (drugdeliverybusiness.com) MiniMed announced FDA clearance of the MiniMed Flex on March 18, 2026, describing a screenless, smartphone‑controlled insulin pump roughly half the size of the MiniMed 780G with a 300‑unit reservoir and SmartGuard adaptive algorithm. (prnewswire.com) MiniMed completed an IPO in early March 2026, pricing 28,000,000 shares at $20.00 per share to begin trading March 6, 2026 and generating roughly $538 million in net proceeds that Medtronic said will support the separation; the Flex clearance arrived within two weeks of the IPO pricing. (news.medtronic.com) Novo Nordisk’s oral semaglutide (Wegovy) pill received FDA approval on December 22, 2025 after OASIS‑4 showed mean weight loss of 13.6% at 64 weeks (16.6% in the hypothetical estimand), Novo announced a planned U.S. roll‑out in early January 2026 with a $149/month self‑pay starter price, and the company notes roughly 3.2 million prior Wegovy prescriptions in the U.S. for the injectable brand. (ajmc.com) Three concrete FP&A levers to quantify now: (1) Senseonics — model annual per‑patient revenue streams as sensor insertion procedure + transmitter + $199 discount program and run scenarios for payor coverage rates (Medicare/private payor mix per Diatribe coverage notes). (diatribe.org) (2) MiniMed — build a 24‑month plan that ties MiniMed Flex unit shipments to one‑time capex from the IPO (28M shares at $20), production ramp timelines, and sensor‑compatibility accessory ASPs to estimate gross‑margin expansion. (news.medtronic.com) (3) Wegovy pill — create scenario rows for new monthly starts, conversion from injectable to oral at 5%/15%/30% rates, ARR per patient at $149/month (~$1,788/year), and payer reimbursement levels tied to the SELECT/MACE claim to quantify EBITDA impact to manufacturers and downstream script‑level margins. (prnewswire.com)
